ASSESSMENT OF EFFICACY AND SAFETY OF ORAL FOSFOMYCIN SINGLE DOSE IN UNCOMPLICATED URINARY TRACT INFECTION AT A TERTIARY CARE HOSPITAL IN SOUTH INDIA

SASHIDHAR REDDY B; MANOJ KUMAR YADAV M; MANISHA S; SANGI REDDY SAI SREE; SUNKARA HEMA KAMALA

doi:10.22159/ajpcr.2022.v15i2.43133

Authors

SASHIDHAR REDDY B Department of General Medicine, RVM Institute of Medical Sciences and Charitable Trust Hospital, Siddipet, Telangana, India.
MANOJ KUMAR YADAV M Department of General Medicine, RVM Institute of Medical Sciences and Charitable Trust Hospital, Siddipet, Telangana, India.
MANISHA S Department of General Medicine, RVM Institute of Medical Sciences and Charitable Trust Hospital, Siddipet, Telangana, India.
SANGI REDDY SAI SREE Department of General Medicine, RVM Institute of Medical Sciences and Charitable Trust Hospital, Siddipet, Telangana, India.
SUNKARA HEMA KAMALA Department of General Medicine, RVM Institute of Medical Sciences and Charitable Trust Hospital, Siddipet, Telangana, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i2.43133

Keywords:

Urinary tract infection, Fosfomycin trometamol, Effectiveness, Adverse effects

Abstract

Objectives: Urinary tract infection (UTI) affects 150 million people worldwide each year. The rise in the UTIs is attributed to multidrug-resistant pathogens for which there are minimal treatment options available. This has facilitated the reemergence of certain old antimicrobials such as fosfomycin trometamol (FT). It seems an alternative, but the evidence towards its therapeutic efficiency is scanty. The objective of the study is to evaluate the safety and efficacy of single dose of FT in treating uncomplicated UTI and the resultant variations in the intensity of symptoms after the treatment.

Methods: The study is a prospective, observational, and open-label study in the outpatient unit of the Department of General Medicine, RVM institute of Medical Sciences, for 6 months. The study comprises 50 patients among the age group of 18–70 years. Urinary Tract Infection Symptom Assessment questionnaire was used for the evaluation of symptoms pre and post treatment. After the diagnosis of uncomplicated UTI, patients were treated with single-dose of FT.

Results: The study comprises 22 males and 28 females. After the treatment, there was a drastic improvement in the condition of patients. The severity level reduced and the quality of life improved post treatment and the results were statistically significant. Among 50 patients treated with the drug, 11 patients reported the side effect of diarrhea.

Conclusion: Single dose oral Fosfomycin (3 g) regimen is effective in managing uncomplicated UTI with minimal side effects.

Downloads

Download data is not yet available.

References

Manish M, Vaibhav R, Shankar S. Fosfomycin single-dose oral antibiotic for uncomplicated UTI a review. Indian Pract 2019;72:34-41.

Medina M, Pino EC. An introduction to the epidemiology and burden of UTI. Ther Adv Urol 2019;11;3-7.

Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim- Raz N, et al. Effect of 5 day nitrofurantoin vs single dose Fosfomycin on clinical resolution of uncomplicated lower UTI in women; a randomized clinical trial. JAMA 2018;319:1781-9.

Cai T. Recurrent uncomplicated UTI; definition and risk factors. GMS Infect Dis 2021;9:Doc03.

Bradley JG, Andrew JS, Iain JA, Anton YP. Nitrofurantoin and fosfomycin for resistant urinary tract infections: Old drugs for emerging problems. Aust Prescr 2019;42:14-9.

Bedi P, Singh K, Wariach P. Study of fosfomycin trometamol in acute lower urinary tract infection. J. Evol Med Dent Sci 2016;5:1649-50.

Clayson D, Wild D, Doll H, Karen K, Gondek K. Validation of a patient administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in an uncomplicated UTI: The UTI symptom assessment questionnaire. BJU Int 2005;96:350-9.

Dmitri I, Ronald W, John F, Sumathi N. Adverse events associated with fosfomycin use: Review of literature and analyses of FDA adverse event reporting system database. Infect Dis Ther 2015;4:433-58.

Stein GE. Comparison of single dose of Fosfomycin and a 7 day course of nitrofurantoin in female patients with uncomplicated UTI. Clin Ther 1999;21:1864-72.

Speight TM, Holford NH. Avery’s Drug Treatment: Guide to Properties, Choice, Therapeutic Use, Economic Value of Drugs in Disease Management. Vol. 2. India: Wiley; 2012. p. 1072-3.

Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison’s Principles of Internal Medicine, Part-8: Infectious Diseases. New York: McGraw Hill; 19th ed. 2016. p. 861-4.

Antimicrobial Use in Common Syndromes Treatment Guidelines by ICMR New Delhi, Chapter-9, Management of UTI’s; 2019. p. 86-92.

Ralston S, Penman I, Strachan M, Hobson R. Davidson’s Principles and Practice of Medicine. 23rd ed., Ch. 17. London, United Kingdom: Churchill Livingstone; 2017. p. 511-3.

Raz R. Fosfomycin: An old new antibiotic. Clin Microbiol Infect 2012;18:4-7.

Aghamali M, Sedighi M, Bialvaei AZ, Mohammadzadeh N, Abbasian S, Ghafouri Z, et al. Fosfomycin mechanisms and the increasing prevalence of resistance. J Med Microbiol 2018;68:11-25.

Ahmed B, Clarker L, Doi Y, Shields RK. Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of literature. Diagn Microbiol Infect Dis 2019;95:114856.

Ten Doesschate T, van Werkhoven H, Meijvis S, Stalenhoef J, van Zuilen A, de Vries A, et al. Fosfomycin trometamol for UTIs in kidney transplant recipients. Transplantation 2019;103:1272-6.

Mai C, Donaghy H, Doan T. Oral fosfomycin use for urinary tract infections and its clinical impact on hospital stay. Open Forum Infect Dis 2018;5 Suppl 1:S473.

Dijkmans AC, Zacarias NV, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, et al. Fosfomycin: Pharmacological, clinical and future perspectives. Antibiotics (Basel) 2017;6:24.

Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M, Scarborough M, et al. Oral fosfomycin for treatment of urinary tract infection a retrospective cohort study. BMC Infect Dis 2016;16:556.

Qiao LD, Zheng B, Chen S, Yang Y, Zhang K, Guo HF, et al. Evaluation of three dose fosfomycin tromethamine in treatment of patients with urinary tract infections: An uncontrolled, open label, multicenter study. BMJ Open 2013;3:e004157.

Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multi drug-resistant organisms. Antimicrob Agents Chemother 2012;56:5744-8.

de Jong Z, Pontonnier F, Plante P. Single dose fosfomycin trometamol(Monuril) versus multiple dose norfloxacin results of multicenter study in females with uncomplicated lower urinary tract infections. Urol Int 1991;46:344-8.

Stein GE. Single dose treatment of acute cystitis with fosfomycin tromethamine. Ann Pharmacother 1998;32;215-9.